Stocks Health care LIVN
NASDAQ · Health careLivaNova PLC (LIVN)
LivaNova PLC brought in $1.5B of revenue over the twelve months to September 30, 2026, up 11.7% from a year earlier. Net income was $196.1M, a net margin of 13.0%. Operating cash flow minus capital spending left $173.3M of free cash flow in fiscal 2025. At September 30, 2026 it held $563.5M in cash against $295.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about LivaNova PLC
- Net worth
- LivaNova PLC has a market value (market cap) of $5.1B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.4B (+10.7% year on year), with a net loss of $242.5M. Over the 12 months to September 30, 2026: revenue $1.5B, net income $196.1M.
- Cash flow
- In fiscal 2025 operations brought in $254.3M of cash; after $81.1M of capital spending, free cash flow was $173.3M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- LivaNova PLC's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What LivaNova PLC does
LivaNova PLC is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NASDAQ under the ticker LIVN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4B | -$242.5M | -$4.45 | $173.3M |
| 2024 | $1.3B | $63.2M | $1.16 | $135.9M |
| 2023 | $1.2B | $17.5M | $0.32 | $39.9M |
| 2022 | $1B | -$86.2M | -$1.61 | $43.4M |
| 2021 | $1B | -$135.8M | -$2.68 | $77.1M |
| 2020 | $934.2M | -$348.8M | -$7.18 | -$114.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LIVN ranks in Health care
Latest SEC filings
What LivaNova PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Form IRANNOTICE filing IRANNOTICE
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9.9% to $393.1M versus the same quarter last year; diluted EPS $0.11 versus $0.49.
- November 4, 2026
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Form IRANNOTICE filing IRANNOTICE
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $390.6M versus the same quarter last year; diluted EPS $1.93 versus $0.50.
- August 5, 2026
- June 11, 2026
- May 29, 2026
What is LIVN worth? A DCF from its reported cash flow
Insider trades
What the people running LivaNova PLC did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $591.8K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Bianchi FrancescoDirector | Sold | 3,500 | $273K |
| September 4, 2026 | Story BrookeDirector | Sold | 2,300 | $187.3K |
| August 31, 2026 | Bianchi FrancescoDirector | Sold | 1,650 | $131.5K |
| August 11, 2026 | Tezel AhmetChief Innovation Officer | Exercised options | 12,692 | $668.6K |
| August 11, 2026 | Tezel AhmetChief Innovation Officer | Other change | 8,589 | $668.7K |
| August 11, 2026 | Tezel AhmetChief Innovation Officer | Shares withheld for tax | 1,428 | $111.2K |
| August 11, 2026 | Tezel AhmetChief Innovation Officer | Sold | 2,675 | $207.9K |
| June 15, 2026 | Zurbay DonaldDirector | Exercised options | 2,560 | - |
Who owns LIVN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Primecap Management Co13G, passive | 7.74% | February 12, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.8% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 303 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 7,565,342 | +426,434 |
| Primecap Management Co | 4,168,377 | -38,675 |
| Fmr LLC | 3,147,068 | +480,394 |
| Hood River Capital Management LLC | 2,565,477 | +1,928,937 |
| Aqr Capital Management LLC | 2,356,191 | -138,181 |
| Invesco Ltd. | 2,237,319 | +613,110 |
| Artisan Partners Limited Partnership | 2,224,763 | +101,947 |
| State Street Corp | 2,165,863 | +93,184 |
| American Century Companies Inc | 2,013,774 | +218,839 |
| Dimensional Fund Advisors LP | 1,845,285 | +19,037 |
| Geode Capital Management, LLC | 1,755,648 | +257,877 |
| Wellington Management Group Llp | 1,739,167 | -151,482 |
| Congress Asset Management Co | 1,502,244 | +227,424 |
| Vanguard Portfolio Management LLC | 1,414,832 | +70,543 |
| Greenhouse Funds LLLP | 924,128 | +155,833 |
| Victory Capital Management Inc | 851,820 | +18,552 |
| Emerald Advisers, LLC | 787,101 | +116,894 |
| Nuveen, LLC | 727,968 | -192,375 |
| Northern Trust Corp | 697,776 | +31,466 |
| Goldman Sachs Group Inc | 695,721 | -103,230 |
Insiders
16 insiders reported holding 213,181 shares in total, about $19.7M at the last price.
| Holder | Shares |
|---|---|
| Shvartsburg AlexChief Financial Officer | 44,647 |
| Kozy William ADirector | 37,566 |
| Bolton StephaniePresident, Global Epilepsy | 22,189 |
| Enxing Seng StacyDirector | 15,307 |
| Makatsaria VladimirChief Executive Officer, Director | 14,167 |
| Schermerhorn Todd CDirector | 12,619 |
| Poletti FrancoPresident, Cardiopulmonary | 10,755 |
| Wilver Peter MDirector | 10,294 |
| Barry James ChristopherDirector | 7,918 |
| Story BrookeDirector | 7,488 |
Questions about LIVN
What does LivaNova PLC do?
LivaNova PLC is a company in the Health care sector, listed on NASDAQ as LIVN. Its shares trade on NASDAQ under the ticker LIVN.
What is LivaNova PLC's net worth?
LivaNova PLC has a market value (market cap) of $5.1B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is LivaNova PLC profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $196.1M on revenue of $1.5B, a net margin of 13.0%.
How much revenue does LivaNova PLC make?
Over the twelve months to September 30, 2026 LivaNova PLC reported revenue of $1.5B. That is 11.7% more than a year earlier.
When did LivaNova PLC last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is LivaNova PLC's next earnings report?
LivaNova PLC's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LIVN with
Follow LIVN
Get an email when LivaNova PLC files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values LivaNova PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.